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Background: The Multiple Sclerosis Neuropsychological Screening Questionnaire (MSNQ) was developed for
screening of MS patients at risk for cognitive impairment with a patient self-report (MSNQ-P) and an infor-
mant version (MSNQ-I). The objective of this study was to validate the Dutch versions and determine their
interpretability.
Methods: The MSNQ was completed by 121 MS patients and their partners (informants). We investigated the
factor structure, internal consistency and construct validity. Interrater reliability between MNSQ-P and
MSNQ-I was investigated with the intraclass correlation coefﬁcient (ICC) and Cohen's kappa. For interpret-
ability of both MSNQ versions we calculated sensitivity, speciﬁcity and cut-off scores. Receiver operating
characteristic (ROC) curves with related area under the curve (AUC) were used to evaluate the added
value of combining both versions.
Results: We found a unidimensional factor structure. Cronbach's alphas were 0.93 and 0.94 for MSNQ-P and
MSNQ-I, respectively. The ICC was 0.59 and kappas were ≤0.50. No cut-off score could be deﬁned for the
MSNQ-P because of low sensitivity. For the MSNQ-I, sensitivity was 0.75 and speciﬁcity 0.71 (AUC 0.80).
The cut-off score was 21. ROC curve analyses showed no added value of the MSNQ-P when used in combina-
tion with the MSNQ-I.
Conclusions: The MSNQ-I is preferred over the MSNQ-P to screen MS patients for cognitive impairment.© 2012 Elsevier B.V. Open access under the Elsevier OA license.1. Introduction
Cognitive impairment in multiple sclerosis (MS) is common, occur-
ring in 40–70% of MS patients [1]. It can occur in any stage of the disease
and it is associated with problems in activities of daily living, employ-
ment, social functioning and a reduced quality of life [2].
Decline in cognitive functioning can be tested using neuropsychol-
ogical tests. However, there are several disadvantages of neuropsychol-
ogical testing. First, it is time-consuming and may be burden for some
patients. Second, it is expensive since there is a need for qualiﬁed
staff. Therefore a short screening instrument is needed to identify
patients who might be cognitively impaired and in whom additional
formal neuropsychological testing is useful [3]. Such a short screening
instrument may even be used to indicate possible cognitive decline in
MS patients in (long term) follow-up studies.ter, Department of Epidemiol-
The Netherlands. Tel.: +31 20
).
sevier OA license.The Multiple Sclerosis Neuropsychological Screening Questionnaire
(MSNQ) [3] is a self-report questionnaire that was developed to screen
MS patients at risk for cognitive impairment. The MSNQ consists of 15
items and reﬂects neuropsychological competence during activities in
daily living. In addition to the MSNQ for patient self-report (MSNQ-P),
an informant form was developed (MSNQ-I) to compare the opinion
of the patient about cognitive problems in daily life with the opinion
of an informant.
Studies in the United States [3–5] and Argentina [6] tested the
psychometric properties of both versions of the MSNQ. In these studies
moderate to high Cronbach's alphas were found [3–6]. Test–retest
correlations were only calculated in one study and they were also
found to be high [4]. Construct validity was investigated by calculating
the relationship of the MSNQ with neuropsychological testing and de-
pression. All previous studies found high correlations between the
MSNQ-P score and depression and low correlations between MSNQ-P
score and cognitive impairment. In contrast, the MSNQ-I was positively
correlated with cognitive impairment and not with depression of the
patient.
Comparison of MSNQ scores with an instrument that measures
cognitive impairment provides information about the validity of the
(change) scores of the MSNQ. Interpretability is the degree to which
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Repeatable Battery for Neuropsychological Tests (BRB-N) [8–10] is
widely used to measure cognitive impairment. A recent study compar-
ing neuropsychological test batteries concluded that the BRB-N is reli-
able and sensitive to use in MS patients [11]. The BRB-N measures
different aspects of cognition in ﬁve subtests. In MSNQ validation stud-
ies [3,4,6] cut-off scores were deﬁned, based on measures of cognitive
impairment, for the interpretability of MSNQ scores. These cut-off
scores were different in all studies. In most of the validation studies
no discriminative value was found for the MSNQ-P because of low sen-
sitivity [3,5,6].
The ﬁrst objective of this study was to validate the Dutch version
of the MSNQ-P and MSNQ-I in a large sample of Dutch MS patients
and informants. The psychometric properties were investigated by
determining the structure of the MSNQ, internal consistency and con-
struct validity. In addition, interrater reliability and agreement be-
tween patient and informant scores were investigated.
The second objective was to determine the interpretability of the
MSNQ. Using sensitivity and speciﬁcity we tried to calculate cut-off
scores for both versions to identify patients at risk for cognitive im-
pairment. For that purpose, the BRB-N subtest scores were used as
an external criterion. Receiver operating characteristic (ROC) curves
with related area under the curve (AUC) were used to evaluate the
added value of combining both versions.2. Methods
2.1. Study sample
The subjects in this study were 121 MS patients and 121 infor-
mants, partners of MS patients. Patients were participating in ongoing
research projects at the MS Center of the VU University Medical
Center Amsterdam and their visit was already scheduled for these
projects. The medical ethical committee of the VU University Medical
Center approved the study protocol. The characteristics of the study
sample are shown in Table 1.2.2. Translation of MSNQ
A forward and backward translation procedure of the original
English version [3] was followed to develop the Dutch version of
the MSNQ patient and informant form. Both versions were translated
into Dutch by two independent researchers followed by an indepen-
dent backward translation into English. The backward translation
was compared with the original version. In only three items minorTable 1
Characteristics of the study sample.
Patient Proxy
Malea 46 (38) 73 (60)
Femalea 75 (62) 48 (40)
Age in yearsb 53 (45–63) 55 (45–63)
Relapsing Remitting (RR)a 43 (36) na
Secondary Progressive (SP)a 40 (33) na
Primary Progressive (PP)a 34 (28) na
Clinically Isolated Syndrome (CIS)a 4 (3) na
Disease duration in yearsb 15 (9.0–22.0) na
EDSSb 4.5 (3.0–6.5) na
High education (college/university)a 37 (30) 38 (31)
Moderate education (secondary school)a 40 (33) 42 (35)
Low educated (primary school)a 42 (35) 40 (33)
Completion of MSNQ in hospital settinga 121 (100) 87 (72)
EDSS, Expanded Disability Status Scale.
a N (%).
b Median (IQR).differences were observed which were dealt with in consensus by
adapting the wording of the Dutch version.
2.3. Tests and procedures
Patients were asked to complete the MSNQ-P and other question-
naires (described below) and were invited to perform a number of
neuropsychological tests. The informant (partner of patient) was asked
to complete the MSNQ-I in the hospital waiting room or it was complet-
ed at home and returned using a prepaid envelope.
TheMSNQ versions for patient self report and informant contain the
same items but from another perspective. The 15 MSNQ items have 5
response options, 0 (does not occur) to 4 (very often, very disruptive).
A total score is computed with a range from 0 to 60, a higher score indi-
cates more cognitive problems.
The Hospital Anxiety and Depression Scale (HADS) [12] is a 14-item
self-report screening scale to indicate the possible presence of anxiety
(7 items) and depressive states (7 items). For both continuous scales
the range of scores is 0 to 21. The HADS is validated in different groups
of Dutch subjects (three groups of healthy controls >18 years and gen-
eral, somatic and psychiatric patient groups) [13].
The BRB-N was developed as a short observational instrument to
identify disturbances of cognitive domains in MS patients. The BRB-N
(version A) consists of ﬁve subtests. Immediate and delayed recall
memory is assessed by the Selective Reminding Test (SRT) [14]; visuo-
spatial immediate and delayed recall memory is assessed by the Spatial
Recall Test (SPART) [15]; the Rao version [9] of the Symbol Digit
Modalities Test (SDMT) [16] examines processing speed and concentra-
tion by primarily assessing complex and visual scanning and tracking;
the Rao version [9] of the Paced Auditory Serial Addition Test (PASAT)
[17] measures information processing speed and interference suppres-
sion in the 2 and 3 second tests; and the Word List Generation (WLG)
test [8] assesses semantic verbal ﬂuency. For each of the ﬁve subtests
a score is obtained. An abnormal score for each subtest was deﬁned
with the most stringent criterion, i.e. two standard deviations below
themean reported for Dutch healthy subjects [18]. Patients were classi-
ﬁed in three levels of cognitive functioning, no impaired subtest score
(no cognitive impairment), 1 or 2 impaired subtest score(s) (group at
risk) and 3 ormore impaired subtest scores (cognitively impaired) [19].
The Expanded Disability Status Scale (EDSS) [20] was used as a
standardized neurological examination. The EDSS assesses neurological
impairment and disability and was performed by a trained doctor.
EDSS score varies between 0 and 10, a high score indicates amore severe
disability.
3. Data analysis
3.1. Validity
Factor analyses (principal component analyses) were done to inves-
tigate the factor structure of each MSNQ version separately. We hypoth-
esized that theMSNQ items load on one general factor. In addition to the
principal component analysis we used parallel analysis to compare the
unrotated eigenvalues from a random sample, with the same number
of cases and variables,with our data. If the eigenvalues from the principal
component analysis were found to be higher than the eigenvalues from
the parallel analysis, it was signiﬁcant and we could retain the factor.
We calculated Cronbach's alpha for both scales to determine their
internal consistency. Cronbach's alpha above 0.70 was considered to
be appropriate [21].
Construct validity was tested by deﬁning hypotheses. It examines
whether the MSNQ score represents the theoretical concept of inter-
est, i.e. neuropsychological competence [22]. We tested the following
hypotheses based on results from earlier studies [3–6]. Since the data
were not normally distributed, Spearman correlations were used.
Table 2
Factor loadings from principal component analysis.
MSNQ-P MSNQ-I
1. Distractibility 0.71 0.69
2. Problems with listening to others 0.70 0.78
3. Slowed processing 0.74 0.77
4. Forgetting appointments 0.64 0.72
5. Forgetting what is read 0.78 0.83
6. Forgetting shows or programs 0.78 0.80
7. Forgetting instructions 0.79 0.86
8. Needing frequent reminders 0.76 0.86
9. Failing to follow through on planned activities 0.59 0.69
10. Failing to answer questions coherently 0.78 0.80
11. Failing to track two things at once 0.83 0.86
12. Failing to follow conversations 0.78 0.81
13. Problems controlling impulses 0.59 0.52
14. Laughing or crying without cause 0.57 0.55
15. Excessive egocentric speech 0.50 0.57
MSNQ-P,Multiple Sclerosis Neuropsychological Screening Questionnaire— patient version;
MSNQ-I, Multiple Sclerosis Neuropsychological Screening Questionnaire — informant
version.
Table 3
Spearman correlations.
Mean SD Correlations
MSNQ-P MSNQ-I
MSNQ-P 18.4 10.3 na 0.52
MSNQ-I 17.1 11.2 0.52 na
Age 52.8 11.7 0.20 0.19
Gender patient na na −0.03 −0.24
Education (level) na na −0.13 −0.13
Disease duration (years) 16.9 8.8 0.26 0.17
EDSSa 4.5 3.0–6.5 0.33 0.38
HADS anxiety 4.9 3.2 0.47 0.33
HADS depression 4.1 3.5 0.49 0.36
BRB-N global (amount impaired out of
5 subtests)
0.6 1.2 0.26 0.39
SRT — immediate recall, long term storage 46.0 14.8 −0.28 −0.29
SRT — immediate recall, consistent long
term storage
35.6 15.9 −0.22 −0.34
SRT — delayed recall 46.1 16.0 −0.17 −0.36
SPART — immediate recall (3) 29.0 15.5 −0.21 −0.37
SPART — delayed recall 8.6 2.9 −0.13 −0.32
SDMT 19.8 5.1 −0.06 −0.02
Pasat 3″ — correct 6.8 2.4 −0.12 −0.14
Pasat 2″ — correct 47.1 15.1 −0.27 −0.34
WLG 24.4 7.4 −0.17 −0.30
MSNQ-P,Multiple Sclerosis Neuropsychological Screening Questionnaire— patient version;
MSNQ-I, Multiple Sclerosis Neuropsychological Screening Questionnaire — informant
version; EDSS, Expanded Disability Status Scale; HADS, Hospital Anxiety and Depression
Scale; BRB-N, Brief Repeatable Battery for Neuropsychological Tests; SRT, Selective
Reminding Test; SPART, Spatial Recall Test; SDMT, Symbol Digit Modalities Test; PASAT,
Paced Auditory Serial Addition Test; WLG, Word List Generation.
a Median, IQR.
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0.40) between MSNQ-P score and amount of impaired subtests on
the BRB-N.
2. There is a moderate and positive correlation (i.e. correlation be-
tween 0.40 and 0.70) between MSNQ-I score and amount of im-
paired subtests on the patient BRB-N.
3. There is a moderate and positive correlation (i.e. correlation be-
tween 0.40 and 0.70) between MSNQ-P and patient HADS score.
4. There is a small positive correlation (i.e. correlation between 0 and
0.40) between MSNQ-I and patient HADS score.
5. The correlation between MSNQ-I and amount of impaired cogni-
tive tests is higher than the correlation between MSNQ-P and im-
paired cognitive tests (difference≥0.10).
6. The correlation between MSNQ-P and patient depression is higher
than the correlation between MSNQ-I and patient depression
(difference≥0.10).
Interrater reliability between patient and informant on scale level
was evaluated using the intraclass correlation coefﬁcient two-way
mixed model for absolute agreement (ICCagreement) [23]. Cohen's
weighted kappa (κw) [24] was calculated to evaluate interrater reli-
ability between patient and informant on item level, using quadratic
weights. The weighted kappas were calculated for all items. ICC and
kappa above 0.70 were considered to be appropriate [21].
Agreement was measured with the Limits of Agreement. In a
Bland and Altman [25] plot the differences between patient and
proxy scores were plotted against the mean score of each pair on
the MSNQ. The limits of agreement (LoA) were calculated using the
mean difference per scale (đ) and the standard deviation of the
mean difference (SDdifference):
LoA ¼ đ  1:96SDdifference:
3.2. Interpretability
One of the objectives of this study was to calculate cut-off scores for
theMSNQ that best classiﬁes patients in the study sample as cognitively
impaired. The scores on the BRB-N subtests were used as a criterion to
classify patients in three levels of cognitive functioning. We calculated
sensitivity and speciﬁcity for each MSNQ version separately and for
thatweused 3ormore impaired subtest scores as cutoff for cognitive im-
pairment. In additionwe repeated the analyses using 1 ormore impaired
subtest score(s) as cutoff for cognitive impairment. We considered the
optimal cut-off score for both MSNQ versions to be the value for which
[1-sensitivity]+[1-speciﬁcity] is the smallest. Because the goal of this in-
strument is to screen for cognitive impairment,we considered sensitivity
to be more important than speciﬁcity.
Receiver operating characteristic (ROC) curves were constructed
using logistic regression models in which the presence of cognitive im-
pairment was the dependent variable and MSNQ-P and MSNQ-I were
entered either alone or both together as independent variables. We
compared the area under the curve (AUC) of MSNQ-P, MSNQ-I and
the combined line.
All statistical analyses were performed using the Statistical Package
for Social Sciences (SPSS) version 14.0 (SPSS, Inc., Chicago, IL, USA) and
Stata 11.1 (StataCorp, College Station, TX 2009).
4. Results
4.1. Missing items
Three patients and 4 informants had one missing MSNQ item. In
these cases, the mean item score of the scale was imputed. In one
case more than a single item was missing and this case was excluded
from analyses.4.2. Psychometric properties
The results of the factor analysis (principal component analysis)
are displayed in Table 2. The items of both MSNQ versions loaded
high on their ﬁrst factor. The eigenvalue of this factor was 7.5 for
MSNQ-P and explained 50% of the variance. The highest loading was
0.83 for item 11 (i.e. failing to track two things at once) and the low-
est loading was 0.50 for item 15 (i.e. excessive egocentric speech).
The ﬁrst factor of the MSNQ-I explained 56% of the total variance
and the eigenvalue was 8.4. The highest loading for the informant
version was 0.86 for the items 7, 8 and 11 (i.e. forgetting instructions,
needing frequent reminders and failing to track two things at once)
and the lowest was 0.52 for item 13 (i.e. problems controlling im-
pulses). In the parallel analyses was seen that the eigenvalues of
this sample were much higher than the eigenvalue of a random sam-
ple. Some items also loaded on a second factor in the principal
Table 4
Weighted kappa: interrater reliability of MSNQ items.
κw 95% CI
MSNQ 1 0.32 0.11–0.49
MSNQ 2 0.36 0.17–0.52
MSNQ 3 0.25 0.07–0.44
MSNQ 4 0.39 0.22–0.58
MSNQ 5 0.50 0.33–0.62
MSNQ 6 0.50 0.35–0.65
MSNQ 7 0.43 0.27–0.58
MSNQ 8 0.43 0.24–0.58
MSNQ 9 0.28 0.11–0.44
MSNQ 10 0.47 0.30–0.62
MSNQ 11 0.49 0.32–0.64
MSNQ 12 0.46 0.28–0.61
MSNQ 13 0.42 0.26–0.57
MSNQ 14 0.42 0.20–0.60
MSNQ 15 0.35 0.17–0.55
MSNQ, Multiple Sclerosis Neuropsychological Screening Questionnaire; κw, weighted
kappa; CI, conﬁdence interval.
94 J.M. Sonder et al. / Journal of the Neurological Sciences 320 (2012) 91–96component analysis (eigenvalue MSNQ-P 1.35 and MSNQ-I 1.17), but
when looking at the parallel analysis we could not retain this factor.
Therefore, we can conﬁrm the unidimensional structure of the MSNQ.
Cronbach's alpha analyses showed good internal consistency; 0.93
for MSNQ-P and 0.94 for MSNQ-I.
Spearman correlations were calculated between MSNQ-P and
MSNQ-I, and all other variables. The results of these correlations are
presented in Table 3 with variable means and standard deviations
(SD).
All hypotheses were conﬁrmed concerning the construct validity:
1. The correlation between MSNQ-P score and amount of impaired
subtests on the BRB-N was 0.26, small positive.
2. The correlation between MSNQ-I score and amount of impaired
subtests on the BRB-N was 0.39, almost moderate and positive, al-
though just below the hypothesized value of 0.40.
3. Both patient depression (0.49) and anxiety (0.47) scales of the HADS
showed amoderate and positive correlation with theMSNQ-P score.
4. The correlations between MSNQ-I and patient anxiety and depres-
sion score were 0.36 and 0.33 respectively, both small positive.Fig. 1. Limits of Agr5. The correlation between MSNQ-P and impaired BRB-N subtests
was 0.26, for MSNQ-I this correlation was 0.39. The difference in
correlation between the MSNQ versions and amount of impaired
BRB-N subtests was 0.13, more than 0.10.
6. The correlations between MSNQ-P and patient anxiety and depres-
sion were respectively 0.47 and 0.49, for the MSNQ-I these correla-
tions were 0.33 and 0.36 respectively. The differences in correlations
were both more than 0.10.
Interrater reliability between the patient and informant version on
scale level was moderate. The ICC of MSNQ-P total score and MSNQ-I
total score was 0.59 (95% CI: 0.46–0.69), which indicated that the
MSNQ-P and MSNQ-I were not able to discriminate patients similarly.
Interrater reliability on item level was also moderate. None of the
kappa values reached the limit of 0.70. Weighted kappa values (κw)
for item scores are shown in Table 4with their conﬁdence intervals (CI).
The Bland and Altman plot is displayed in Fig. 1. Themean difference
was +1.3, meaning that the mean score of patients was 1.3 points
higher than the mean score of informants (i.e. systematic error). The
limits of agreement (i.e. random error) were between −17.7 and
+20.4 (range−60 to +60).
4.3. Interpretability
Patients were classiﬁed in three levels of cognitive functioning, no
impaired subtest score (no cognitive impairment), 1 or 2 impaired
subtest scores (group at risk) and 3 or more impaired subtest scores
(cognitively impaired). Of all MS patients in this sample, 39 patients
(32%) had one or more abnormal scored subtests and 12 patients
(10%) were classiﬁed as cognitively impaired because of 3 or more ab-
normal subtests (Table 5).
We could not deﬁne a cut-off score for the MSNQ-P because sensi-
tivity (0.42) was found to be too low and not discriminative for cog-
nitive impairment (3 or more impaired subtest scores). The optimal
cut-off score in our data for the MSNQ-I was 21, with a sensitivity of
0.75 and a speciﬁcity of 0.71. The ROC curves are shown in Fig. 2.
The AUC of MSNQ-I was 0.80 (95% CI 0.65–0.95), equal to the com-
bined line of MSNQ-P and MSNQ-I. Also when including the group
at risk (1 or 2 abnormal subtest scores) in the cognitively impairedeement MSNQ.
Table 5
Classiﬁcation of BRB-N subtest results.
BRB-N N
No impaired subtest score 82 68%
1 or 2 impaired subtest scores 27 22%
3 or more impaired subtest scores 12 10%
BRB-N, Brief Repeatable Battery for Neuropsychological Tests.
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and equal to the combination of MSNQ-I and MSNQ-P.
5. Discussion
In this study about the validation and interpretation of the Dutch ver-
sion of the MSNQ we found a clear unidimensional factor structure for
both versions. Internal consistencywas good for both scales. Assessment
of construct validity showed that all hypotheses based on previous
studies [3–6] were conﬁrmed. As expected, we found a higher correla-
tion between the MSNQ-P and patient anxiety and depression (mea-
sured with the HADS) than between MSNQ-P and impaired cognitive
subtests (measured with the BRB-N). In contrast, MSNQ-I correlates
higher with the amount of impaired subtests compared to the correla-
tion with anxiety or depression. Therefore, we recommend to use the
MNSQ-I version.
The interrater reliability of the total score and the item scores be-
tween the patient and informant versions was moderate. The MSNQ-P
is not able to identify cognitive disabled patients as good as the
MSNQ-I does. Interrater agreement was poor. Although the systematic
error between patient and informant version was low, the random
error (i.e. Limits of Agreement)was large. Ninety-ﬁve percent of the dif-
ferences between patient and informant were between −17.7 and
+20.4. Since the range of the scale was 0 to 60, and therefore the differ-
ence between patient and informant could have a maximum variation
between −60 and 60, the random error is huge. No signiﬁcant differ-
ences were found between the group of informants participating in
the hospital or at home (data not shown). However, it cannot be exclud-
ed that better results might have been obtained under more strictly
controlled conditions.
In some earlier published studies about the MSNQ [3,5,6] re-
searchers found low sensitivity for the MSNQ-P and no cut-off scoreFig. 2. ROC curves.could be deﬁned. Also in this study we found a sensitivity that was
too low to deﬁne a clear cut-off score for the patient version. The sen-
sitivity and speciﬁcity of the informant version were better than the
patient version. We could deﬁne a cut-off score of 21 for the Dutch
version of the MSNQ-I, which was almost equal to results of earlier
studies in North America [4]. Analyses showed that when combining
MSNQ-I and MSNQ-P there was no added value of the patient version.
Some challenges were encountered when comparing our data with
existing data because of the differences in the design and execution of
previous studies. There were differences in measurement instruments
and patient groups. Cognitive tests, used as the external standard,
were not the same in all published studies about the sensitivity and de-
termining cut-off scores for the MSNQ. Only the Argentinean study [6]
used the BRB-N, but the classiﬁcation of impaired patients was different
compared to our study. In our study only a small number of patients
were classiﬁed as cognitively impaired according to neuropsychological
testing. Patients were participating in ongoing research projects and it
cannot be excluded that this may have caused some selection bias to-
wards less cognitively impaired patients. Furthermore it should be
noted that the BRB-N as used in this study is missing a measure of
higher executive functioning, which could have inﬂuenced the results.
There were also differences in measuring depression in the published
studies. Other researchers [3–6] used Beck's Depression Inventory —
Fast screen (BDI-FS) [26], some in combination with the Center for Ep-
idemiologic Studies Depression scale (CES-D) [3,4,27] while we used
the HADS for measuring depression as well as anxiety. These issues
may explain some of the observed differences in the results.
Future studies would beneﬁt from selecting more MS patients with
cognitive impairment, so that the relationship between cognitive test-
ing and the MSNQ can be tested more speciﬁcally. In addition we
would recommend to collect test–retest data. These studies should
also address the origin of disagreement between patients and infor-
mants on theMSNQ.With the growing interest in self assessment scales
understanding the background of disagreement is of increasing impor-
tance. It has been subject to research before and possible explaining fac-
tors are depression, anxiety and caregiver burden [28–30].
In summary, in this study we investigated the validity and inter-
pretability of the MSNQ. The main outcome is that the MSNQ-I is
more promising to screen for cognitive impairment in MS patients.
The patient version has no added value, so when screening for cogni-
tive impairment in MS the MSNQ informant version is preferred.Conﬂict of interest
I declare herewith that all authors report no ﬁnancial or
non-ﬁnancial conﬂicts of interest.References
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